top of page

GPCR News 

Post: Blog2_Post

Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...

April 2022


Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage of its Evolution


"New team focused on expanding its GPCR-focused structure-based drug design platform and enhancing translational medicine capabilities


• ‘Venture-like’ capital allocation approach to focus pipeline development through to Phase 1b/2a clinical proof of concept in patients, and optimize value generation


• Mid-term global expansion plans include drug discovery technology investments, licensing late-stage products for Japan, and strategic acquisitions


• Mr. Chris Cargill appointed as President and Chief Executive Officer


• Dr. Matt Barnes appointed President of Heptares Therapeutics Ltd., and Head of UK R&D


Tokyo, Japan and Cambridge, UK, 24 March 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) today confirms that a series of Executive Management changes have been approved at the Company’s 32nd Shareholders’ Meeting today and are effective immediately (see biographies at the end)."


2 views0 comments

Recent Posts

See All

Comments